COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.

COVID-19 Reactogenicity SARS-CoV-2 Vaccine safety

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
22 Mar 2024
Historique:
received: 04 12 2023
revised: 04 03 2024
accepted: 11 03 2024
medline: 24 3 2024
pubmed: 24 3 2024
entrez: 23 3 2024
Statut: aheadofprint

Résumé

GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection. Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity. Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1-2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects. We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.

Sections du résumé

BACKGROUND BACKGROUND
GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection.
METHODS METHODS
Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity.
RESULTS RESULTS
Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1-2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects.
CONCLUSIONS CONCLUSIONS
We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.

Identifiants

DOI: 10.1016/j.vaccine.2024.03.030 PMID: 38521677
pubmed: 38521677
pii: S0264-410X(24)00317-7
doi: 10.1016/j.vaccine.2024.03.030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jennifer Taher reports financial support was provided by Canadian Institutes of Health Research for this study. JT also received in-kind funding from Roche for projects unrelated to the current manuscript. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Gregory Morgan (G)

Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.

Selina Casalino (S)

Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.

Sunakshi Chowdhary (S)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.

Erika Frangione (E)

Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.

Chun Yiu Jordan Fung (CYJ)

Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.

Elisa Lapadula (E)

Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.

Saranya Arnoldo (S)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada; William Osler Health System, Brampton, ON L6R 3J7, Canada.

Erin Bearss (E)

Mount Sinai Academic Family Health Team, Mount Sinai Hospital, Toronto, ON M5T 3L9, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada.

Alexandra Binnie (A)

Department of Critical Care, William Osler Health System, Etobicoke, ON M9V 1R8, Canada.

Bjug Borgundvaag (B)

Schwartz/Reisman Emergency Medicine Institute, Sinai Health System, Toronto, ON M5G 2A2, Canada.

Laurent Briollais (L)

Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada.

Marc Dagher (M)

Department of Family and Community Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada; Women's College Hospital, Toronto, ON M5S 1B2, Canada.

Luke Devine (L)

Division of General Internal Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada; Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.

Steven M Friedman (SM)

Department of Family and Community Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada; Emergency Medicine, University Health Network, Toronto, ON M5G 2C4, Canada.

Zeeshan Khan (Z)

Mackenzie Health, Richmond Hill, ON L4C 4Z3, Canada.

Chloe Mighton (C)

Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON M5B 1A6, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada.

Konika Nirmalanathan (K)

Emergency Medicine, University Health Network, Toronto, ON M5G 2C4, Canada.

David Richardson (D)

William Osler Health System, Brampton, ON L6R 3J7, Canada.

Seth Stern (S)

Mackenzie Health, Richmond Hill, ON L4C 4Z3, Canada.

Ahmed Taher (A)

Mackenzie Health, Richmond Hill, ON L4C 4Z3, Canada; Division of Emergency Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada.

Dawit Wolday (D)

Department of Biochemistry & Biomedical Sciences, McMaster University, Hamilton, ON L8S 4K1, Canada.

Jordan Lerner-Ellis (J)

Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.

Jennifer Taher (J)

Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: jennifer.taher@sinaihealth.ca.

Classifications MeSH